{
  "id": "dialysis",
  "title": "Dialysis",
  "lang": "en",
  "source_lang": "en",
  "summary": "Dialysis separates dissolved substances across a semipermeable membrane and is chiefly used to replace part of kidney function.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Kidney dialysis",
    "renal dialysis"
  ],
  "generated_at": "2026-10-13",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/dialysis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/dialysis/",
      "json": "https://aiwiki.page/zh/dialysis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Dialysis is the separation of dissolved substances through a semipermeable membrane, principally by diffusion. In medicine, the term chiefly refers to treatments that remove metabolic wastes and excess water from the blood when the kidneys cannot do so adequately. Dialysis also helps regulate electrolytes and acid–base balance, supporting aspects of homeostasis. Its two principal clinical forms are hemodialysis, which uses an external filter, and peritoneal dialysis, which uses the membrane lining the abdominal cavity. The same separation principle is used in laboratory work, including the purification of proteins. (assets.thermofisher.com)\n\nDialysis can sustain life in kidney failure and provide temporary support during acute kidney injury, but it replaces only some kidney functions and does not itself cure the underlying disease. Its effectiveness depends on membrane transport, treatment delivery, access to the bloodstream or abdominal cavity, and monitoring of both clearance and clinical condition. The subject encompasses the development of artificial kidneys, different treatment modalities, complications and long-term outcomes, and the organization of services within the health system. (niddk.nih.gov)"
    },
    {
      "heading": "Definition, Terminology, and Clinical Scope",
      "text": "Dialysis is a membrane-mediated separation process in which dissolved substances move selectively between two fluid compartments. In its physicochemical sense, it principally involves diffusion through a selectively permeable membrane: molecules able to cross the membrane move down their concentration gradients, while larger or otherwise poorly permeant substances remain largely confined to their original compartment. The membrane separates the fluids without requiring them to mix directly. This meaning extends beyond medicine; in biochemistry, for example, dialysis can remove salts and small reagents from a solution while retaining proteins. The defining feature is selective transfer across a membrane, not the use of a particular machine or the treatment of a particular disease. (assets.thermofisher.com)\n\nIn clinical usage, dialysis predominantly means treatment that removes retained waste substances and excess water from the blood when the kidneys cannot maintain adequate internal balance. It also helps correct electrolyte and acid–base disturbances, but does not replace every kidney function or cure the underlying disease. Two principal forms are hemodialysis, which passes blood through a dialyzer outside the body, and peritoneal dialysis, which introduces dialysis fluid into the abdominal cavity and uses the peritoneal lining as the exchange membrane. Thus, clinical dialysis need not involve circulating blood outside the body; both forms accomplish separation between blood and dialysis fluid across a membrane. (niddk.nih.gov)\n\nKidney replacement therapy (KRT) is the broader clinical category encompassing dialysis and kidney transplantation. The older expression renal replacement therapy (RRT) denotes the same category and remains present in earlier guidelines and publications. A Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference held in June 2019, with recommendations published in 2020, preferred “kidney” over “renal” in descriptions of kidney function and disease. Dialysis and kidney transplantation are distinct components of KRT: dialysis provides membrane-based treatment, whereas transplantation supplies a functioning donor organ. Clinical modality classifications also include hemofiltration and hemodiafiltration, which employ related membrane-based processes but differ in their transport mechanisms. (kdigo.org)\n\nFor acute kidney injury (AKI), dialysis can provide temporary support while native kidney function recovers. Treatment may therefore stop once the kidneys can adequately meet the body’s needs; the 2012 KDIGO AKI guideline explicitly identified sufficient recovery of intrinsic kidney function as a reason to discontinue replacement therapy. Starting dialysis during an acute illness does not, by itself, establish permanent kidney failure. Conversely, recovery is not assured, and severe AKI can leave persistent impairment requiring longer-term treatment. (kdigo.org)\n\nMaintenance dialysis denotes ongoing treatment for kidney failure associated with chronic kidney disease, generally when sufficient recovery is not expected. It may continue long term or serve as a bridge to transplantation. KDIGO terminology distinguishes short-term from long-term or maintenance dialysis rather than relying on “acute dialysis” and “chronic dialysis,” because acute and chronic more precisely describe the underlying disease. Treatment duration, modality, and disease duration are separate descriptors: receiving intermittent rather than continuous treatment does not establish whether kidney failure is temporary or permanent. (kdigo.org)"
    },
    {
      "heading": "Membrane Transport and Solute Removal",
      "text": "Diffusion transfers dissolved substances across a selectively permeable membrane from higher to lower concentration, without requiring bulk water movement. Transport is bidirectional: each permeating solute follows its own concentration gradient, rather than all substances moving out of blood together. A simplified description is \\(\\dot{M}=PA(C_b-C_d)\\), where \\(\\dot{M}\\) is the solute transfer rate, \\(P\\) its effective membrane permeability, \\(A\\) the available membrane area, and \\(C_b-C_d\\) the concentration difference between blood and dialysis fluid, or dialysate. Increasing area or permeability increases transport; increasing membrane thickness lengthens the diffusion path and reduces transport when other properties remain unchanged. Pore diameter, pore density, and molecular shape also influence passage, so membrane selectivity is not an absolute molecular-weight threshold. (assets.thermofisher.com)\n\nFluid flow maintains the gradients on which diffusion depends. Without renewal or mixing, solute accumulates on the receiving side and the concentration difference declines toward equilibrium. Hemodialyzers therefore ordinarily arrange blood and dialysate in countercurrent flow, moving in opposite directions on either side of the membrane. This preserves a concentration difference along the exchange surface. Blood and dialysate flow also affect the resistance presented by fluid layers next to the membrane; clearance consequently depends on the complete flow system, not membrane properties alone. Diffusive clearance expresses solute removal as an equivalent volume of blood or plasma cleared per unit time and should not be confused with the volume of water removed. (assets.thermofisher.com)\n\nUltrafiltration is bulk water passage through the membrane driven by a net transmembrane pressure difference. In hemodialysis, the hydrostatic pressure difference between blood and dialysate promotes filtration, while osmotic effects associated with retained plasma proteins oppose outward water movement. Hydraulic permeability determines how readily water crosses at a given driving pressure. Osmosis, by contrast, describes water movement caused by differences in osmotic activity across a selectively permeable barrier. Peritoneal dialysis uses dextrose or icodextrin in the abdominal dialysis solution to establish an osmotic driving force for water removal. Thus, solute diffusion and water removal have distinct driving forces and need not change in parallel. (pmc.ncbi.nlm.nih.gov)\n\nConvective solute transport occurs when permeating substances accompany filtered water, a process often termed solvent drag. The membrane’s sieving coefficient describes the concentration of a solute in filtrate relative to its concentration in the source fluid: a value near one indicates relatively unrestricted passage, whereas a value near zero indicates retention. Under simplified conditions, convective clearance is approximately the filtration rate multiplied by the sieving coefficient. Increasing filtration therefore improves removal only for substances able to traverse the pores. Hemodiafiltration combines this mechanism with diffusion; its total filtered volume can exceed the patient’s net fluid loss because replacement fluid is supplied, a distinction developed in the discussion of treatment modalities. (pmc.ncbi.nlm.nih.gov)\n\nMolecular size helps explain differences in removal. Small, freely dissolved compounds such as urea and creatinine pass readily through conventional membranes. The traditional classification separates small water-soluble compounds below approximately 500 daltons from larger “middle molecules,” including peptides and small proteins such as beta-2-microglobulin. Larger molecules require sufficiently permeable membranes, and convection contributes importantly to their removal. Essential circulating proteins, notably albumin, are generally retained by standard membranes; a membrane permeable to beta-2-microglobulin is not necessarily permeable to larger plasma proteins. (journals.plos.org)\n\nProtein binding creates a separate limitation: a chemically small substance can be poorly removed when most of it is attached to a retained carrier protein. The freely dissolved fraction is accessible for passage, while continued removal depends on dissociation from the carrier and replenishment from other body compartments. In a 2016 study by Sunny Eloot and colleagues, median protein binding was 93% for indoxyl sulfate and 95% for p-cresyl sulfate. Across the investigated solutes, greater binding was associated with lower dialyzer clearance. Their transfer between body compartments was also slower than that of urea, demonstrating why efficient urea removal does not establish equally efficient removal of protein-bound substances. (journals.plos.org)"
    },
    {
      "heading": "Kidney Functions Replaced and Functions Not Replaced",
      "text": "Dialysis partially replaces the excretory and regulatory functions of the kidneys, removing retained waste products and helping maintain fluid, electrolyte, and acid–base balance. Urea, produced during nitrogen metabolism, is an important example of a removable waste and is commonly measured to assess treatment performance. Its removal does not, however, establish that all retained substances have been adequately cleared. Native kidneys combine filtration with selective tubular reabsorption and secretion; dialysis does not reproduce this cellular processing. A 2013 experimental study demonstrated that healthy kidneys efficiently clear numerous protein-bound solutes through tubular secretion, whereas these substances can remain at substantially elevated concentrations in patients receiving hemodialysis. Examples include indoxyl sulfate and p-cresyl sulfate. Thus, replacing waste excretion is not equivalent to reproducing the kidneys’ complete biochemical selectivity. (niddk.nih.gov)\n\nRemoval of excess water and sodium helps regulate extracellular fluid volume, reducing fluid accumulation and contributing to control of edema and blood pressure. Dialysis also adjusts electrolyte concentrations, particularly potassium, while the composition of the dialysis fluid influences calcium and other mineral balances. Acid–base correction supplies buffer rather than restoring the kidneys’ normal acid-excretion machinery: bicarbonate delivered through hemodialysis fluid helps counter the accumulation of acids generated by metabolism. These functions remain only partially replaced, so fluid and biochemical control also depend on accompanying medical care and any remaining kidney activity. (niddk.nih.gov)\n\nThe temporal pattern of replacement differs markedly from continuous native kidney function. Conventional in-center hemodialysis commonly consists of three sessions each week, lasting approximately four hours each—about 12 treatment hours in a 168-hour week. Waste production and fluid intake continue between sessions, creating alternating periods of accumulation and removal rather than steady regulation. Longer or more frequent treatments can reduce these fluctuations but still do not reproduce every kidney function. Residual kidney function is therefore important even after dialysis begins: surviving nephrons continue working between treatments and can contribute disproportionately to clearance of substances poorly removed by dialysis. A 2011 study found that residual function made a greater relative contribution to removal of protein-bound solutes than to removal of urea. (niddk.nih.gov)\n\nDialysis does not restore normal production of erythropoietin, the kidney-derived hormone that stimulates bone marrow to produce red blood cells. Reduced erythropoietin production in advanced chronic kidney disease contributes to anemia, although iron deficiency, inflammation, blood loss, and shortened red-cell survival can also contribute. Erythropoiesis-stimulating agents provide a pharmacological signal to the marrow, while iron treatment addresses deficient iron availability. These are accompanying treatments, not effects of dialysis itself: an injection or infusion given during a hemodialysis session remains distinct from membrane-mediated waste and fluid removal. (niddk.nih.gov)\n\nThe kidneys also activate vitamin D to form calcitriol, which supports calcium balance and bone mineralization. Kidney failure impairs this activation and reduces phosphate excretion; altered calcium and phosphate balance can stimulate increased parathyroid hormone secretion. Dialysis removes some phosphate and modifies mineral concentrations, but it does not restore normal vitamin D activation or the coordinated hormonal regulation of bone and mineral metabolism. Active vitamin D preparations or analogues, phosphate-binding medicines, and other treatments address these abnormalities separately. Phosphate binders, for example, reduce intestinal phosphate absorption rather than extracting phosphate from blood through the dialysis membrane. (niddk.nih.gov)"
    },
    {
      "heading": "Clinical Indications and Treatment Initiation",
      "text": "Dialysis is initiated when impaired kidney function produces complications that cannot be adequately controlled by other treatment, or when life-threatening disturbances require rapid correction. Major indications include severe fluid overload, particularly pulmonary edema; dangerous electrolyte abnormalities, especially hyperkalemia; and severe metabolic acidosis. In acute kidney injury, the decision considers the broader clinical situation and trends in laboratory results rather than an isolated blood urea or creatinine concentration. Symptomatic uremia is another indication: manifestations attributable to kidney failure include encephalopathy, pericarditis, anorexia, otherwise unexplained weight loss, intractable itching, and bleeding. These findings differ in urgency; neurological complications or pericarditis may require prompt treatment, whereas progressive nutritional deterioration may lead to a scheduled start. (kdigo.org)\n\nIn chronic kidney disease, estimated glomerular filtration rate (eGFR) informs assessment but does not independently determine when dialysis begins. The 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guideline specifies a composite assessment of symptoms, signs, quality of life, preferences, filtration rate, and laboratory abnormalities. Indications also include inability to control fluid volume or blood pressure, progressive deterioration in nutritional status despite dietary intervention, and cognitive impairment attributable to kidney failure. Such indications often—but not invariably—arise at a GFR of \\(5–10\\ \\mathrm{mL/min/1.73\\,m^2}\\); this range is not an automatic treatment threshold. Predialysis assessment can additionally document functional capacity, muscle strength, gait speed, and symptom burden, helping distinguish declining daily function from a laboratory change alone. (kdigo.org)\n\nEvidence against routine filtration-rate–driven early initiation comes from the IDEAL randomized controlled trial, published in 2010 by Bruce A. Cooper and colleagues. Across 32 centers in Australia and New Zealand, 828 adults with progressive kidney disease were assigned to planned initiation at estimated GFR values of \\(10–14\\) or \\(5–7\\ \\mathrm{mL/min/1.73\\,m^2}\\). During a median follow-up of 3.59 years, mortality was 37.6% in the early-start group and 36.6% in the late-start group; the hazard ratio was 1.04, with a 95% confidence interval of 0.83–1.30. Early initiation did not significantly improve survival or clinical outcomes. Importantly, 75.9% of the late-start group began treatment above the assigned threshold because symptoms developed: the trial tested monitored deferral, not withholding dialysis despite clinical indications. (pubmed.ncbi.nlm.nih.gov)\n\nUrgency and preparedness describe separate dimensions of initiation. The 2019 KDIGO conference report defined an urgent start as treatment required imminently or within 48 hours of presentation to correct life-threatening manifestations, and a nonurgent start as one that can occur after 48 hours. A planned start requires prior selection of the modality and access ready for use; an unplanned start includes unavailable usable access, a start requiring hospitalization, or initiation with a modality other than the patient’s choice. Thus, an unplanned start is not necessarily an emergency. Preparation precedes treatment: the 2024 guideline identifies GFR below \\(15–20\\ \\mathrm{mL/min/1.73\\,m^2}\\), or a predicted two-year kidney-replacement-therapy risk above 40%, as circumstances for access planning rather than automatic dialysis initiation. (kdigo.org)\n\nExtracorporeal removal of selected poisons constitutes a separate indication, potentially even without kidney failure. Removability depends on molecular size, protein binding, distribution between blood and tissues, and endogenous clearance. Lithium illustrates favorable properties: its small molecular size, negligible protein binding, and relatively limited volume of distribution permit substantial removal by hemodialysis. EXTRIP recommendations identify severe lithium poisoning with decreased consciousness, seizures, or life-threatening dysrhythmias as indications for extracorporeal treatment irrespective of the measured lithium concentration. For methanol poisoning, indications include coma, seizures, new visual deficits, or severe acidosis. Toxicological initiation therefore depends on the particular substance and clinical toxicity, not on a renal filtration threshold alone. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Hemodialysis Equipment and Treatment Circuit",
      "text": "The extracorporeal blood circuit carries blood from a vascular access through disposable tubing to a dialyzer and then back to the patient. In a conventional two-line circuit, the withdrawal tubing is called the arterial line and the return tubing the venous line, regardless of whether the access is a fistula, graft, or catheter. Blood passes a pressure-monitoring connection, is propelled by a blood pump, and enters the dialyzer. After leaving the dialyzer, it passes through a venous chamber, air detector, and safety clamp before returning to the circulation. The reusable machine drives and monitors this circuit; blood remains within the tubing and dialyzer rather than entering the machine’s internal hydraulic system. (niddk.nih.gov)\n\nA hollow-fiber dialyzer contains a bundle of thin membrane tubes within a housing. Blood flows through the fiber interiors, while dialysate flows around their exteriors, normally in the opposite direction. This countercurrent arrangement maintains concentration differences along the device and supports diffusive solute removal. The fiber walls separate the two fluids: their controlled permeability permits movement of water and selected solutes without direct bulk mixing of blood and dialysate. Membrane materials include synthetic polymers, such as polysulfone and polyarylethersulfone, and modified cellulose, such as cellulose triacetate. A randomized crossover study published in 2021, for example, compared dialyzers made from these three material classes, illustrating that hollow-fiber construction does not imply a single membrane chemistry. (niddk.nih.gov)\n\n“Low-flux” and “high-flux” describe membrane transport characteristics, not the speed of the blood pump. Low-flux dialyzers principally remove small solutes such as urea and creatinine; high-flux devices have greater water permeability and better removal of middle-sized molecules, including beta-2 microglobulin. The ultrafiltration coefficient, \\(K_{\\mathrm{UF}}\\), expresses the volume of water transferred per unit time and transmembrane pressure, commonly in milliliters per hour per millimeter of mercury for a complete dialyzer. Membrane material alone does not determine flux: synthetic membranes can be manufactured in either category. High-flux permeability makes precise machine control of net fluid removal particularly important. (freseniusmedicalcare.com)\n\nThe blood pump commonly uses rollers that compress a flexible tubing segment. Arterial and venous pressure sensors help identify excessive resistance, obstruction, or circuit disconnection. A venous air chamber separates bubbles from flowing blood; detection of air can trigger an alarm, stop the pump, and close the return-line clamp. On the dialysate side, temperature regulation and conductivity monitoring check heating and concentrate proportioning, while unsafe readings cause dialysate bypass. Conductivity reflects overall ionic concentration rather than separately measuring every electrolyte. A blood-leak detector monitors spent dialysate for evidence of membrane failure. Balancing chambers and an ultrafiltration pump regulate the difference between dialysate inflow and outflow, allowing fluid removal to be controlled independently of blood-pump speed. (freseniusmedicalcare.com)\n\nBlood contact with artificial surfaces activates coagulation, creating a risk of clotting in tubing, chambers, and hollow fibers. Clots can reduce effective membrane area, interrupt treatment, and prevent recovery of blood remaining in the circuit. Anticoagulation therefore forms part of circuit management. The Renal Association’s 2019 hemodialysis guideline identifies unfractionated or low-molecular-weight heparin for patients without increased bleeding risk, while specifying that systemic anticoagulation may be reduced or omitted when bleeding risk is increased. Alternatives include selected heparin-free approaches and regional citrate anticoagulation, which lowers available ionized calcium within the circuit. These approaches differ in equipment and monitoring requirements; anticoagulation prevents circuit clotting but does not substitute for pressure, air, or blood-leak surveillance. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Vascular Access for Hemodialysis",
      "text": "An arteriovenous fistula (AVF) is created by surgery joining an artery directly to a vein, usually in the arm. Increased flow enlarges the vein and thickens its wall, making it suitable for repeated needle insertion. This adaptation, called maturation, takes weeks to months; some fistulas fail to become usable or require additional procedures. An arteriovenous graft (AVG) instead connects an artery and vein through a synthetic tube beneath the skin. The graft itself provides the puncture surface and generally becomes usable sooner, although healing time depends on its design. Functioning fistulas usually last longer and have fewer infections and clots than grafts, but their usefulness depends on successful maturation. (niddk.nih.gov)\n\nA central venous catheter provides separate lumens for withdrawing and returning blood through a large central vein, without repeated needle puncture. Unlike a fistula, it can be used immediately after placement. Nontunneled catheters provide short-term access, while tunneled, cuffed catheters pass beneath the skin before entering the vein and are designed for longer use. Catheters commonly bridge an urgent dialysis start or the interval before an AV access becomes usable; they may also remain the access in selected circumstances when other options are unsuitable. Their limitations include infection, clot-related dysfunction, and central venous narrowing that can compromise future access. (kidney.org)\n\nCannulation of a fistula or graft normally uses two needles: one withdraws blood into the extracorporeal circuit and the other returns it. Needle placement requires an accessible segment capable of supporting the prescribed blood flow. Clinical monitoring includes inspection, palpation of the thrill—the vibration produced by flowing blood—and assessment of the audible bruit. New cannulation difficulty, prolonged puncture-site bleeding, arm swelling, altered access sounds, or inability to achieve the intended flow can indicate dysfunction. Instrument-based surveillance, such as access-flow measurement or ultrasound, supplements rather than replaces this assessment. The 2019 Kidney Disease Outcomes Quality Initiative (KDOQI) guideline distinguishes detection of narrowing from evidence that preventive intervention will improve access survival; an abnormal surveillance result alone does not establish a need for treatment. (niddk.nih.gov)\n\nStenosis narrows the access circuit and can impair flow or contribute to thrombosis, which may abruptly make the access unusable. Investigation relates imaging findings to clinical abnormalities; treatment can involve balloon angioplasty, clot removal, or surgical revision. A separate complication, access-related hand ischemia, occurs when the arteriovenous connection reduces perfusion of the distal limb. Manifestations range from coolness and tingling to pain during dialysis, rest pain, and, in severe cases, tissue loss. Physical examination and vascular testing help distinguish this complication from other causes of hand symptoms. (kidney.org)\n\nInfection risk differs substantially by access type: fistulas have the lowest risk, grafts an intermediate risk, and central venous catheters the highest. Catheter connections and the skin exit site provide opportunities for microbial entry. In a CDC analysis published in February 2023 using 2020 data from 4,840 United States dialysis facilities, the adjusted rate ratio for Staphylococcus aureus bloodstream infection was 6.2 for central venous catheters and 2.2 for the combined “graft or other” category, relative to fistulas. These figures describe a particular organism and surveillance population, not universal rates for all access infections. (cdc.gov)\n\nIndividualized planning considers vascular anatomy, the likelihood and time required for maturation, anticipated treatment duration, previous access failures, functional status, and patient preferences. Vessel preservation and the availability of future access sites also matter. The KDOQI 2019 update, published in 2020, placed access selection within an “ESKD Life-Plan” encompassing expected dialysis modalities and transplantation, rather than applying “fistula first” indiscriminately. A fistula’s potential long-term advantages therefore have to be considered alongside the possibility of maturation failure and prolonged catheter exposure while awaiting usability. (kidney.org)"
    },
    {
      "heading": "Peritoneal Dialysis and Its Modalities",
      "text": "Peritoneal dialysis places dialysis fluid inside the abdominal cavity rather than passing blood through an external dialyzer. The peritoneum, which lines this cavity and covers abdominal organs, provides the exchange surface between circulating blood and the fluid. Small dissolved wastes move into the fluid by diffusion, while an osmotic gradient draws water out of the circulation. A permanent abdominal catheter provides access for the fill–dwell–drain cycle: fresh solution enters, remains for a specified dwell period, and is then drained with accumulated wastes and water. Replacing the drained solution restores the gradients that drive exchange. (niddk.nih.gov)\n\nContinuous ambulatory peritoneal dialysis (CAPD) uses manual exchanges without a machine. Common schedules involve about four exchanges daily, with daytime dwells lasting approximately four to six hours and a longer overnight dwell; the patient can move about while fluid remains in the abdomen. Automated peritoneal dialysis (APD) uses a programmable cycler to perform repeated exchanges, usually during sleep. The cycler warms incoming solution and records fluid delivery and drainage. A typical nighttime schedule contains three to five exchanges, although the prescription varies. APD may include a prolonged daytime dwell or an additional manual exchange; it does not necessarily mean that the abdomen is empty throughout the day. (niddk.nih.gov)\n\nDialysis solutions contain sterile water, electrolytes, a buffer, and an osmotic agent. For example, U.S. Dianeal PD-2 formulations contain sodium at 132 mmol/L and lactate at 40 mmol/L, together with chloride, calcium, and magnesium; their labeled dextrose concentrations are 1.5%, 2.5%, and 4.25%. Dextrose—glucose—creates the osmotic gradient responsible for ultrafiltration, or net water removal. Higher concentrations provide a stronger initial gradient, but glucose absorption progressively weakens it during a dwell. An alternative for prolonged exchanges is icodextrin, a starch-derived glucose polymer that produces colloid osmotic water movement. The U.S. icodextrin formulation contains 7.5% polymer and is labeled for one daily long dwell of eight to sixteen hours in either CAPD or APD. (dailymed.nlm.nih.gov)\n\nDwell duration interacts with the individual membrane’s solute-transfer rate. In a fast transporter, dissolved substances equilibrate relatively quickly, but glucose also disappears from the cavity more rapidly. Consequently, a prolonged glucose-based dwell may yield little net ultrafiltration or allow fluid reabsorption. Shorter glucose exchanges, often delivered by APD, and icodextrin for a long dwell are prescription options identified in the International Society for Peritoneal Dialysis’s 2021 recommendations. Solute transfer and water removal are distinct properties: rapid equilibration does not itself establish satisfactory fluid removal. (pubmed.ncbi.nlm.nih.gov)\n\nMembrane assessment commonly uses the peritoneal equilibration test (PET), a standardized four-hour dwell with specified glucose concentrations and creatinine as the index solute. The 2021 recommendations place initial testing six to twelve weeks after treatment begins, with subsequent testing when clinically indicated. PET findings inform dwell lengths and solution selection, while measured drainage assesses ultrafiltration. For a four-hour test using 4.25% dextrose, net ultrafiltration below 400 mL indicates possible insufficient ultrafiltration capacity. Low drainage alone does not prove intrinsic membrane dysfunction: mechanical catheter problems, leaks, and increased fluid absorption can also contribute and require separate evaluation. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Hemofiltration, Hemodiafiltration, and Intensive-Care Modalities",
      "text": "Hemofiltration removes solutes predominantly by convection: a transmembrane pressure gradient drives plasma water through a permeable filter, carrying dissolved substances with it by solvent drag. Unlike predominantly diffusive hemodialysis, it does not require dialysate flowing on the opposite side of the membrane. The volume filtered for solute clearance substantially exceeds the intended net fluid loss, so replacement fluid is infused into the blood circuit to restore most of the extracted water and electrolytes. Hemodiafiltration combines this convective process with diffusion into dialysate. Its convection volume comprises replacement-fluid volume plus net ultrafiltration; it must therefore be distinguished from the volume actually removed from the patient. In online hemodiafiltration, the machine generates sterile, non-pyrogenic substitution fluid from specially treated dialysis fluid rather than relying exclusively on prepared fluid bags. (freseniusmedicalcare.com)\n\nContinuous kidney replacement therapy (CKRT), also termed continuous renal replacement therapy (CRRT), is designed to operate throughout the day. Its principal venovenous modalities use pumped blood flow from venous access through an extracorporeal filter and back to the venous circulation. Continuous venovenous hemofiltration (CVVH) uses convection and requires replacement fluid, without dialysate. Continuous venovenous hemodialysis (CVVHD) uses dialysate for predominantly diffusive clearance and does not ordinarily require replacement fluid for solute removal, although net ultrafiltration can remove excess water. Continuous venovenous hemodiafiltration (CVVHDF) uses both dialysate and replacement fluid. Replacement can enter before the filter, termed predilution, or after it, termed postdilution. The RENAL trial, for example, used postdilution CVVHDF with equal prescribed dialysate and replacement-fluid flow rates. (usrenalacute.baxter.com)\n\nProlonged intermittent kidney replacement therapy occupies an intermediate position between short intermittent sessions and continuous treatment. Sustained low-efficiency dialysis (SLED) extends treatment over approximately 6–12 hours while using lower blood and dialysate flow rates than conventional intermittent hemodialysis. Spreading solute and water removal over a longer period reduces the rate of physiological change, while treatment-free intervals permit investigations, procedures, and mobilization. Unlike continuous therapy, however, SLED does not provide uninterrupted fluid and biochemical control. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guideline treated continuous and intermittent modalities as complementary options rather than mutually exclusive treatment pathways. (kdigo.org)\n\nIn critical illness, modality selection reflects circulatory stability, fluid-management requirements, neurological status, and local equipment and staffing. Continuous therapy allows fluid removal to be distributed over many hours and adjusted alongside ongoing infusions and nutrition. KDIGO’s 2020 conference report, led by Marlies Ostermann and colleagues, described continuous treatment as more physiologically appropriate than standard intermittent hemodialysis for hemodynamically unstable patients, while noting that randomized trials had not demonstrated better outcomes with continuous therapy. Continuous treatment is also favored in acute brain injury with increased intracranial pressure, where abrupt osmotic and circulatory changes are undesirable. Intermittent treatment offers faster clearance when rapid correction is required; prolonged intermittent treatment provides another option when slower removal is needed. (kdigo.org)\n\nTreatment intensity is distinct from modality. The 2020 KDIGO conference report specified a delivered continuous-treatment effluent volume of 20–25 mL/kg/h, sometimes requiring a higher prescription to compensate for interruptions. Effluent flow is a measure of treatment intensity, not the patient’s net fluid-loss rate. In the 2009 RENAL trial, 1,508 critically ill adults with acute kidney injury were assigned to CVVHDF prescribed at either 40 or 25 mL/kg/h. Ninety-day mortality was 44.7% in both groups, and hypophosphatemia occurred more frequently with higher-intensity treatment. These findings distinguish adequate biochemical clearance from the assumption that progressively increasing clearance necessarily improves survival. (kdigo.org)"
    },
    {
      "heading": "Treatment Schedules, Locations, and Home Delivery",
      "text": "Conventional in-center hemodialysis is commonly scheduled three times weekly, with sessions lasting about four hours—for example, Monday–Wednesday–Friday or Tuesday–Thursday–Saturday. Staff prepare the equipment, connect the patient, and monitor treatment. Home prescriptions may retain a conventional pattern, use shorter treatments on more days, or extend treatment overnight. Examples described by the US National Institute of Diabetes and Digestive and Kidney Diseases include standard home treatment three times weekly or every other day for 3–5 hours, short daily treatment 5–7 days weekly for 2–4 hours, and nocturnal treatment 3–6 nights weekly. Some centers also provide overnight sessions three nights weekly. Thus, treatment location and treatment intensity are separate characteristics: home hemodialysis is not necessarily daily, and nocturnal hemodialysis is not necessarily home-based. (niddk.nih.gov)\n\nHome-based peritoneal dialysis generally follows a daily rather than thrice-weekly schedule. Continuous ambulatory peritoneal dialysis uses manual exchanges distributed through the day, commonly four to six daily; each exchange occupies approximately 30–40 minutes, while dialysis continues during the intervening dwell. Automated peritoneal dialysis uses a cycler to perform exchanges during sleep, commonly three to five overnight. Depending on the prescription, solution may remain in the abdomen during the day, and an additional daytime exchange may be included. Manual exchanges can be performed away from home in a suitable clean location, whereas automated treatment requires access to the cycler. These arrangements distribute treatment around daily activities but do not eliminate the time needed for preparation, connections, supply handling, and record keeping. (niddk.nih.gov)\n\nHome delivery transfers technical tasks from facility staff to trained patients and, where required, care partners. Hemodialysis training covers equipment operation, vascular-access use, infection prevention, alarm responses, and treatment records. Partner requirements vary among programs. (niddk.nih.gov) For peritoneal dialysis, training emphasizes clean connections, catheter care, exchanges or cycler operation, and recognition of problems requiring clinical contact. The International Society for Peritoneal Dialysis’s 2025 teaching position paper incorporates assessment of the home environment, health literacy, sensory and motor abilities, and individual learning needs. Assistance need not be limited to relatives: its 2024 assisted-dialysis position paper describes support from nurses, healthcare aides, trained lay workers, and paid family members. Such services can enable home treatment when a person cannot independently complete all required tasks; their organization depends on the local health system. (niddk.nih.gov)\n\nThe home must accommodate equipment, deliveries, and clean storage. Hemodialysis equipment may require plumbing or electrical modifications, depending on the system, while peritoneal dialysis requires space for substantial quantities of packaged solution and disposable supplies; automated treatment also requires electricity for the cycler. Utility failures therefore affect different systems differently, and home programs arrange contingency support. (kidney.org) Clinical responsibility remains with the dialysis service: home treatment includes scheduled reviews, laboratory testing, and access to professional help. Some hemodialysis programs monitor treatments over the internet. The 2025 peritoneal-dialysis teaching paper describes 24-hour telephone support and outpatient review every one to three months, together with refresher teaching. Remote oversight supplements rather than replaces training and clinical assessment. (niddk.nih.gov)\n\nIncremental dialysis starts with a lower treatment frequency or intensity when residual kidney function contributes meaningfully to solute and fluid removal, then increases treatment as that contribution declines. An example is twice-weekly rather than thrice-weekly hemodialysis in selected patients. This is a planned prescription, not simply omitted sessions. The 2019 UK haemodialysis guideline calls for intermittent quantification of residual kidney function; subsequent UK implementation guidance includes timed urine collections and reassessment of urine output, biochemical findings, weight, fluid status, and symptoms. Declining residual clearance or deteriorating fluid and biochemical control can require longer or more frequent treatment. Urine production alone does not establish that an incremental schedule remains sufficient. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Dialysis Dose, Adequacy, and Monitoring",
      "text": "Clearance is the effective volume of blood or plasma cleared of a specified solute per unit time, usually expressed in millilitres per minute; it is not the physical volume of blood passing through the dialyzer. Urea serves as a measurable marker of small-solute removal. The urea reduction ratio (URR) describes its fractional decrease during one hemodialysis session:\n\n\\[\\mathrm{URR}=\\frac{C_{\\mathrm{pre}}-C_{\\mathrm{post}}}{C_{\\mathrm{pre}}}\\times100\\%,\\]\n\nwhere \\(C_{\\mathrm{pre}}\\) and \\(C_{\\mathrm{post}}\\) are predialysis and postdialysis blood urea concentrations. A decrease from 50 to 15 mg/dL gives a URR of 70%. URR is simple but does not explicitly account for urea generated during treatment or the effects of fluid removal. (niddk.nih.gov)\n\nKt/V expresses urea clearance relative to the body’s urea distribution volume: \\(K\\) is effective urea clearance, \\(t\\) is treatment time, and \\(V\\) is the distribution volume, approximately total body water. Consistent units make the ratio dimensionless. Clinical estimates use urea kinetic models or equations incorporating pre- and postdialysis concentrations, treatment duration, and fluid removal. Single-pool Kt/V (\\(\\mathrm{spKt/V}\\)) treats the body as one well-mixed compartment; equilibrated Kt/V (\\(\\mathrm{eKt/V}\\)) adjusts for subsequent urea redistribution. The National Kidney Foundation’s 2015 KDOQI guideline specified a target \\(\\mathrm{spKt/V}\\) of 1.4 per session for thrice-weekly hemodialysis, with a minimum delivered value of 1.2. For other schedules, it specified a weekly standard Kt/V target of 2.3 and minimum of 2.1, incorporating ultrafiltration and residual kidney clearance. Standard Kt/V accounts for treatment frequency rather than simply adding session values. (kidneyfoundation.cachefly.net)\n\nThe prescribed dose is the planned clearance and treatment duration; the delivered dose reflects actual treatment. Shortened sessions, interruptions, inadequate blood flow, and dialyzer clotting can reduce delivery. Access recirculation occurs when recently dialyzed blood returns directly to the dialyzer inlet instead of first passing through the systemic circulation, reducing effective clearance. It can also produce an artificially low postdialysis urea result and falsely high calculated dose. After treatment, blood urea rises through early circulatory mixing and later movement from relatively under-cleared tissues; this late rebound generally develops over 30–60 minutes. Standardized sampling is therefore essential. Blood-based dose assessment is commonly performed monthly, while some machines estimate clearance during individual sessions through dialysate conductivity measurements. (niddk.nih.gov)\n\nResidual kidney function is assessed using timed urine collections and corresponding blood solute concentrations, not urine volume alone. Residual urea clearance is calculated from urinary urea excretion per unit time divided by the relevant plasma concentration. In hemodialysis, the changing blood concentration across the interdialytic interval requires appropriate sampling or modeling. Continuous native-kidney clearance cannot simply be added to intermittent session Kt/V without accounting for their different time patterns. When residual clearance contributes to the prescription, repeated measurement detects declining function that would otherwise leave the delivered total clearance below the intended level. (kidneyfoundation.cachefly.net)\n\nPeritoneal-dialysis accounting usually uses a representative 24-hour collection of drained dialysate, a concurrent urine collection when urine is produced, and blood measurements. Peritoneal and renal urea clearances are normalized to \\(V\\), expressed per week, and added to obtain total weekly Kt/V. This weekly value is not directly interchangeable with hemodialysis session Kt/V. The 2006 KDOQI guideline specified a minimum total weekly value of 1.7. The 2020 International Society for Peritoneal Dialysis recommendations, led by Edwina Brown and colleagues, instead emphasized goal-directed assessment: an arbitrary clearance target alone does not establish whether a prescription meets the individual’s needs. (kidneyfoundation.cachefly.net)\n\nUrea-based dose measures do not establish overall adequacy. Monitoring also assesses symptoms, appetite and nutritional status, blood pressure, weight trends, edema, urine output, and net fluid removal. Blood tests evaluate potassium, bicarbonate, phosphate, and other biochemical abnormalities. A satisfactory Kt/V may coexist with fluid overload or poor metabolic control, because these depend on treatment duration, frequency, and processes not captured by urea clearance alone. The 2020 peritoneal-dialysis recommendations explicitly incorporate symptoms, volume status, nutrition, residual function, and quality of life alongside solute measurements. (sciencedirect.com)"
    },
    {
      "heading": "Dialysate, Water Treatment, and Facility Safety",
      "text": "Hemodialysis fluid is commonly prepared at the dialysis machine by proportioning treated water, an acid concentrate, and a separate sodium bicarbonate concentrate. The resulting solution contains sodium, chloride, potassium, calcium, and magnesium; many formulations also contain glucose. Bicarbonate provides the principal buffer for correcting metabolic acidosis, while the acid concentrate contributes acetate or another acid component. Composition is formulation- and prescription-specific rather than universal. For example, the manufacturer’s October 2018 labeling for one NaturaLyte formulation specifies nominal final concentrations of sodium 137 mEq/L, potassium 1 mEq/L, calcium 2.25 mEq/L, bicarbonate 33 mEq/L, and glucose 100 mg/dL. These figures describe that product, not standard targets for all patients. Concentrates must match the machine’s proportioning system; incorrect dilution changes both electrolyte and buffer delivery. (freseniusmedicalcare.com)\n\nMunicipal drinking water requires additional treatment before dialysis use. A typical treatment train includes sediment filtration, softening, two activated-carbon beds in series, fine filtration, and reverse osmosis. Activated carbon removes chlorine, chloramines, and some organic contaminants; reverse osmosis uses pressure across a membrane to reduce dissolved contaminants, bacteria, and endotoxin. These stages address different hazards and are not interchangeable. Chemical surveillance includes contaminants such as aluminum, fluoride, and disinfectant residues, which have caused adverse events when inadequately controlled. Carbon treatment and reverse-osmosis equipment require maintenance because components that remove contaminants can themselves become microbial reservoirs. (cdc.gov)\n\nWater purification does not eliminate the possibility of downstream contamination. Bacteria can multiply in storage tanks, poorly circulating distribution pipes, unused branches, and dialysis-machine fluid pathways. Surface-associated biofilms provide persistent reservoirs, while endotoxins—lipopolysaccharides associated with Gram-negative bacteria—can remain a hazard independently of viable bacterial counts. Consequently, surveillance combines microbiological cultures with endotoxin assays rather than treating either as a substitute for the other. CDC’s environmental guidance advocates monthly testing of both. Control measures include scheduled disinfection of distribution systems, minimizing dead-end piping, and maintaining filters and fluid pathways; the disinfection method and schedule must be compatible with the equipment. Modern systems may incorporate automated heat disinfection, but this does not replace quality surveillance. (cdc.gov)\n\nQuality requirements must be identified by issuing organization and edition. The International Organization for Standardization’s ISO 23500-1:2024, second edition, addresses preparation and quality management, including the dialysis provider’s responsibilities after equipment installation. ISO 23500-5:2024, second edition, specifies minimum chemical and microbiological requirements for finished dialysis fluid and for online-produced substitution fluid used in hemodiafiltration or hemofiltration. Its scope excludes peritoneal-dialysis solutions and prepackaged solutions for continuous kidney replacement therapy. Thus, numerical limits quoted from older AAMI standards in historical guidance should not be presented as undated requirements applying to every contemporary dialysis system. (iso.org)\n\nFacility infection control also addresses transmission pathways unrelated to dialysate quality. CDC’s 2024 Core Interventions specify monthly bloodstream-infection surveillance through the National Healthcare Safety Network, monthly hand-hygiene observations, quarterly observations of vascular-access care, and staff competency assessment on hiring and every 6–12 months. Surveillance rates and audit findings are shared with clinical staff to identify corrective actions. Environmental protocols cover cleaning and disinfection of chairs, countertops, machine exteriors, and reusable equipment between patients, with sufficient disinfectant contact time and a patient-free interval at the station. Clean medication preparation is separated from contaminated equipment and supplies. Dialysis wall boxes and drains require particular attention: their contaminated surfaces can transfer microorganisms through staff hands or equipment even when the treated-water supply meets quality requirements. (cdc.gov)"
    },
    {
      "heading": "Treatment-Related Complications",
      "text": "Intradialytic hypotension occurs when fluid removal and cardiovascular compensation cannot maintain adequate circulating volume and blood pressure. Ultrafiltration may outpace the movement of fluid from tissues into the bloodstream, while impaired cardiac function or autonomic responses limit compensation. Manifestations include dizziness, nausea, weakness, and fainting. The 2020 KDIGO conference report identifies any symptomatic blood-pressure decrease, or a lowest systolic pressure below \\(90\\ \\mathrm{mmHg}\\), as a reason for clinical reassessment rather than a universally sufficient diagnostic definition. Evaluation considers the blood-pressure trajectory, ultrafiltration rate, target weight, medications, and cardiovascular status. Muscle cramps are painful involuntary contractions associated with rapid fluid removal and changes in water and electrolyte balance; they can accompany hypotension but are not equivalent to it. (pmc.ncbi.nlm.nih.gov)\n\nDialysis disequilibrium syndrome is a distinct neurological complication, particularly associated with initial hemodialysis in patients with marked urea accumulation. Rapid removal of urea from blood can exceed its clearance from the brain, creating an osmotic gradient that promotes cerebral edema. Symptoms range from headache and nausea to confusion, seizures, and coma. Its evaluation distinguishes it from other causes of neurological deterioration, including stroke, hypoglycemia, and electrolyte disturbances. (pmc.ncbi.nlm.nih.gov)\n\nBleeding may follow vascular-needle displacement or circuit disconnection; anticoagulation used to prevent circuit clotting can increase bleeding risk. Circuit-related hypersensitivity reactions may involve membranes, sterilant residues, or infused medications and present with itching, wheezing, or hypotension. Uncommon emergencies include hemolysis from mechanical injury or abnormal dialysate and air entry through circuit defects. Hemolysis releases intracellular potassium; air embolism can cause respiratory or neurological deterioration. Clinical assessment examines the timing of symptoms, circuit integrity, treatment exposures, and laboratory findings. (pmc.ncbi.nlm.nih.gov)\n\nPeritoneal-dialysis peritonitis commonly presents with abdominal pain and cloudy drained fluid, although either finding can occur without the other. Causes include contamination during exchanges, catheter-associated infection, and intestinal disease. The International Society for Peritoneal Dialysis (ISPD) 2022 guideline defines diagnosis by at least two of three findings: compatible clinical features; an effluent white-cell count above \\(100/\\mu\\mathrm{L}\\) after a dwell of at least two hours, with more than 50% polymorphonuclear leukocytes; and a positive effluent culture. Evaluation includes effluent cell count, differential, Gram stain, and culture. In short automated exchanges, the neutrophil proportion can be diagnostically important even when the absolute count is lower. Exit-site infection is distinct: the 2023 ISPD recommendations identify purulent discharge, with or without surrounding redness, as its defining finding. Tenderness along the subcutaneous catheter tunnel may indicate deeper infection, assessed by examination and sometimes ultrasound. (journals.sagepub.com)\n\nPeritoneal dialysate raises intra-abdominal pressure, which can reveal or aggravate abdominal-wall hernias and drive leakage around the catheter or through tissue defects. Findings include an abdominal or groin bulge, catheter-site wetness, genital swelling, or unexpectedly low drainage. Leakage into the chest through a diaphragmatic communication can produce a pleural effusion and breathlessness. Clinical examination and targeted imaging distinguish these abnormalities from catheter obstruction and membrane dysfunction. (pmc.ncbi.nlm.nih.gov)\n\nImpaired peritoneal ultrafiltration can reflect rapid glucose absorption, which dissipates the osmotic gradient, reduced membrane water transport, excessive fluid absorption, leakage, or mechanical drainage problems. Persistent fluid retention may manifest as weight gain, edema, and breathlessness. The 2021 ISPD membrane-function recommendations identify net ultrafiltration below 400 mL during a four-hour peritoneal equilibration test using 3.86% glucose—equivalent to 4.25% dextrose—as evidence suggesting low ultrafiltration capacity. This is a standardized assessment threshold, not proof of irreversible membrane failure. Evaluation combines membrane testing with exchange records, catheter function, possible leaks, and residual kidney function. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Nutrition, Medication, and Associated Medical Care",
      "text": "Dialysis removes nutrients as well as retained wastes. Hemodialysis allows amino acids and small peptides to cross the dialyzer membrane, while peritoneal dialysis also loses proteins into drained effluent. Losses of some vitamins, restricted food choices, and poor appetite can further compromise nutritional status. The 2020 Kidney Disease Outcomes Quality Initiative (KDOQI) nutrition guideline specifies a protein intake of 1.0–1.2 grams per kilogram of body weight per day for metabolically stable adults receiving maintenance hemodialysis or peritoneal dialysis; this is a population-specific clinical benchmark, not a universal diet prescription. Protein-energy wasting denotes depletion of body protein and energy reserves, arising from combinations of inadequate intake, nutrient losses, and inflammatory or catabolic illness. Its assessment incorporates dietary intake, weight change, muscle and fat stores, and laboratory findings rather than a single measurement. (kidneyfoundation.cachefly.net)\n\nIn peritoneal dialysis, glucose—usually described as dextrose in solution labeling—provides an osmotic gradient for water removal, but some enters the circulation and contributes to energy intake. These absorbed calories can promote weight gain without supplying protein or replacing other lost nutrients. Consequently, nutritional assessment distinguishes energy obtained from food from that obtained through dialysate. Peritoneal dialysis also removes some vitamins; prescribed renal vitamin preparations may accompany treatment when intake and losses warrant supplementation. Nutrient supplementation is separate from the dialysis procedure itself. (niddk.nih.gov)\n\nFluid and electrolyte management balances intake against residual kidney excretion and dialysis removal. Sodium increases thirst and therefore can increase fluid consumption; retained water contributes to weight gain, edema, and changes in blood pressure. Clinical assessment includes interdialytic weight change, symptoms, blood pressure, and the estimated weight without excess fluid. Potassium requirements differ between modalities: potassium can accumulate between intermittent hemodialysis sessions, whereas daily peritoneal dialysis can remove enough to produce low blood concentrations. Dietary planning therefore follows laboratory results and treatment characteristics rather than applying identical restrictions to every patient. Phosphorus control similarly balances adequate protein intake against phosphate burden, including phosphate-containing food additives. Phosphate binders, such as sevelamer or calcium acetate, reduce intestinal absorption of dietary phosphate; their action complements, rather than duplicates, removal by dialysis. (niddk.nih.gov)\n\nDialysis introduces an additional route of drug elimination. Removal depends on molecular size, protein binding, apparent volume of distribution, and the treatment used: drugs that are small, weakly protein-bound, and concentrated in circulating blood are generally more accessible to extracorporeal clearance than drugs extensively bound to proteins or distributed into tissues. Medication review must account for both reduced native kidney clearance and dialysis-associated removal. A drug may accumulate between treatments yet be substantially removed during a session, making administration timing or a postdialysis supplemental dose clinically relevant. Gabapentin illustrates this distinction: prescribing information reports that, in 11 adults without urine production, its apparent elimination half-life was approximately 132 hours on nondialysis days but 3.8 hours during hemodialysis. These differences require drug-specific review rather than a blanket dosing rule. (pubmed.ncbi.nlm.nih.gov)\n\nAssociated care for anemia addresses functions that dialysis does not restore. Reduced kidney production of erythropoietin lowers red-cell production, while blood loss, nutrient deficiencies, and inflammation can contribute independently. Evaluation includes hemoglobin and iron-status testing. Iron replacement and erythropoiesis-stimulating agents may be administered during dialysis visits, but remain pharmacological treatments rather than effects of filtration. The KDIGO 2026 anemia guideline covers these interventions in dialysis-dependent kidney disease; treatment decisions incorporate symptoms, iron availability, transfusion avoidance, and treatment risks. (niddk.nih.gov)\n\nChronic kidney disease–mineral and bone disorder likewise requires care beyond solute removal. Management considers serial phosphate, calcium, and parathyroid hormone results together. The KDIGO 2017 guideline describes dietary phosphate management, phosphate binders, and dialysis as complementary phosphate-lowering approaches. For dialysis patients requiring reduction of parathyroid hormone, accompanying treatments include calcimimetics, calcitriol, and vitamin D analogues. Their selection depends partly on calcium and phosphate concentrations, because lowering parathyroid hormone can also alter these mineral balances. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Outcomes, Daily Life, and Population Differences",
      "text": "Survival, hospitalization, physical function, and patient-reported quality of life are distinct outcomes: longer survival does not necessarily imply fewer admissions, preserved independence, or lower symptom burden. The United States Renal Data System’s 2025 Annual Data Report, describing 2023 observations, reported an adjusted all-cause mortality rate of 168.4 deaths per 1,000 person-years among adults receiving dialysis. This population rate is not an individual annual probability of death or an estimate of remaining lifespan. Cardiovascular disease remains a major contributor to mortality, while vascular-access infection, thrombosis, and procedures to repair or replace access contribute to hospitalization. Fluid accumulation between treatments can increase blood pressure and cardiac workload; rapid fluid removal can also stress the heart. These pathways coexist with pre-existing cardiovascular illness rather than representing effects of dialysis alone. (usrds-adr.niddk.nih.gov)\n\nPatient-reported outcomes capture experiences that laboratory measurements and survival statistics do not. They include pain, itching, sleep disturbance, mood, fatigue, and the ability to participate in valued activities. The 2023 Kidney Disease: Improving Global Outcomes (KDIGO) symptom-burden conference report described the Dialysis Symptom Index, which assesses 30 patient-identified symptoms, and kidney-specific quality-of-life instruments that distinguish symptoms, disease burden, and effects on daily life. Persistent fatigue and the recovery period after a hemodialysis session are related but separate experiences. A 2023 National Institute of Diabetes and Digestive and Kidney Diseases meeting emphasized that postdialysis recovery commonly takes several hours and that its mechanisms remain incompletely understood. (kdigo.org)\n\nTreatment burden extends beyond time connected to equipment. Conventional in-center hemodialysis commonly occupies approximately four hours on three days each week, with additional time for transport and recovery. Fixed treatment slots can conflict with employment, childcare, and other caregiving responsibilities; travel requires access to treatment at the destination or transport of suitable home equipment. Home treatment offers scheduling flexibility but transfers tasks—including machine preparation, cleaning, record keeping, and supply ordering—to patients and, where involved, care partners. Thus, reduced travel does not eliminate treatment work. Families may absorb both practical responsibilities and the effects of persistent symptoms on household routines. (niddk.nih.gov)\n\nFor children, outcomes include growth, development, school attendance, and participation with peers, not merely biochemical control or survival. Childhood chronic kidney disease can produce short stature, mineral–bone disturbances, and difficulties with concentration and learning; dialysis does not remove the need to monitor these problems. Treatment and appointments may interrupt schooling, while fatigue limits classroom and extracurricular participation. Educational arrangements can include flexible deadlines, tutoring during hospitalization, and treatment scheduled outside school hours where feasible. Home peritoneal dialysis generally involves substantial parental responsibility, with children progressively participating in their own treatment as they mature. (niddk.nih.gov)\n\nAmong older adults, frailty and dependence in everyday activities provide information not conveyed by chronological age alone. In a registry-linked study published in 2009, Manjula Kurella Tamura and colleagues examined 3,702 United States nursing-home residents who began dialysis between June 1998 and October 2000. At 12 months, 58% had died, and only 13% of the original cohort had maintained their predialysis functional status. Function was measured through dependence in seven activities, including eating, dressing, walking, and transferring. These findings describe a particularly dependent institutionalized population, not all older dialysis recipients; the observational association does not establish that dialysis itself caused the decline. (nejm.org)\n\nComparisons between hemodialysis, peritoneal dialysis, and home treatment are vulnerable to confounding and selection effects. Groups differ in age, underlying disease, residual kidney function, frailty, and social resources before outcomes are measured. KDIGO’s 2023 home-dialysis conference report noted that most comparisons are observational, often lack robust measurements of these characteristics, and predominantly concern higher-income settings. Statistical adjustment therefore cannot automatically convert an observed survival or quality-of-life difference into a treatment effect. Registry comparisons require an explicit observation period, population, outcome definition, and adjustment method; associations reported for one health system or patient group need not apply to another. (kdigo.org)"
    },
    {
      "heading": "Transplantation, Conservative Care, and Treatment Transitions",
      "text": "Dialysis can serve as a bridge to kidney transplantation, maintaining fluid, electrolyte, and waste-product control during transplant assessment and the wait for a donor organ. Dialysis may also be required temporarily after transplantation when the donated kidney has delayed function; this does not necessarily mean that the transplant has failed. If a previously functioning transplant loses sufficient clearance capacity, hemodialysis or peritoneal dialysis can again provide kidney replacement while retransplantation or other care pathways are considered. The 2023 Kidney Disease: Improving Global Outcomes (KDIGO) conference report on failing allografts emphasized preparation of dialysis access before treatment becomes necessary. It also treated continuation or withdrawal of immunosuppression as a separate, individualized decision, balancing treatment risks against factors such as the likelihood of retransplantation. (niddk.nih.gov)\n\nAfter acute kidney injury, dialysis may be discontinued when native kidney function has recovered sufficiently to meet the patient’s metabolic and fluid-removal needs, even if function has not returned to its previous level. KDIGO’s 2012 acute kidney injury guideline distinguished this recovery-based discontinuation from withdrawal because treatment no longer accords with the goals of care. Assessment includes urine output, fluid balance, urinary creatinine clearance where interpretable, and blood urea and creatinine trends between intermittent treatments. A low creatinine concentration immediately after dialysis cannot by itself establish recovery, because the treatment removes creatinine. In critical illness, transition from continuous therapy to intermittent dialysis may precede complete discontinuation as circulation stabilizes and support requirements change. (kdigo.org)\n\nTransitions between maintenance modalities may be temporary or permanent. Examples include transfer from peritoneal dialysis to hemodialysis because of recurrent peritonitis, inadequate clearance, or impaired fluid removal, and transfer from center-based hemodialysis to a home modality when circumstances and preferences change. Such transitions require more than a new prescription: they involve suitable vascular or abdominal access, training, reassessment of residual kidney function, and coordination of treatment delivery. KDIGO’s 2019 dialysis-initiation conference report described modality choice as an ongoing process rather than an irreversible decision made at treatment initiation; anticipating a possible transfer can reduce unplanned interruptions and emergency access placement. (kdigo.org)\n\nComprehensive conservative kidney care is active, planned care for kidney failure without dialysis or transplantation. It includes efforts to preserve remaining kidney function, treatment of associated problems such as anemia, symptom management, psychological and family support, and preparation for end-of-life care when appropriate. Its goals include maintaining function and quality of life, rather than replacing kidney filtration mechanically. It is therefore not equivalent to abandonment of treatment, and it does not necessarily imply that death is imminent. Palliative care is one component of conservative management but can also accompany dialysis or transplant care. (niddk.nih.gov)\n\nInformed consent and shared decision-making address the expected benefits, burdens, uncertainties, and alternatives of treatment in relation to the person’s goals. The Renal Physicians Association’s second-edition guideline, published in October 2010, provides a framework for decisions about dialysis initiation and withdrawal. Advance care planning records preferences for future circumstances and identifies a surrogate decision-maker if capacity is lost. Withdrawal discussions include assessment of decision-making capacity, voluntariness, and potentially treatable contributors to distress, including depression; when capacity is absent, prior expressed wishes and the authorized surrogate guide decisions within the applicable framework. When prognosis or treatment benefit is uncertain, a time-limited dialysis trial can establish an agreed reassessment point. Withdrawal of dialysis does not withdraw care: symptom relief, psychosocial and spiritual support, and support for family caregivers remain part of the clinical plan. (kidneysupportivecare.org)"
    },
    {
      "heading": "Historical Development",
      "text": "In 1861, the Scottish chemist Thomas Graham described dialysis as a method of separating substances by their different rates of passage through a membrane. Using vegetable parchment, he distinguished readily diffusible “crystalloids,” such as salts, from poorly diffusible “colloids,” including many macromolecular substances. This work established a laboratory separation technique based on diffusion, rather than a treatment for kidney disease. Its application to circulating blood followed in 1913, when John Jacob Abel, Leonard Rowntree, and B. B. Turner demonstrated an extracorporeal apparatus in animals. Blood flowed through collodion tubes surrounded by fluid, allowing diffusible substances to leave the circulation. In 1924, Georg Haas performed the first human hemodialysis in Giessen, Germany; these early procedures demonstrated technical feasibility but did not establish an effective, sustainable treatment. (urologichistory.museum)\n\nWillem Kolff developed his rotating-drum artificial kidney in Kampen, in the occupied Netherlands, and began treating patients in 1943. Cellophane tubing wound around a rotating drum provided the membrane: blood passed inside the tubing, while rotation repeatedly brought it into contact with the surrounding dialysis bath. Small solutes could cross the cellulose-based membrane while blood cells and larger constituents remained within the circuit. On September 11, 1945, Kolff successfully treated a 67-year-old woman with acute kidney failure, establishing that extracorporeal dialysis could sustain a patient through a reversible episode of kidney dysfunction. The achievement concerned temporary support during recovery, not yet indefinite replacement of kidney function. (blog.sciencemuseum.org.uk)\n\nRepeated access to the circulation remained a central obstacle to maintenance hemodialysis. Earlier methods required repeated insertion of arterial and venous cannulas, progressively exhausting usable blood vessels. In 1960, engineer Wayne Quinton, surgeon David Dillard, and physician Belding Scribner developed an external arteriovenous shunt at the University of Washington. Its Teflon cannulas remained in an artery and an adjacent vein; an external connection allowed blood to circulate between them when dialysis was not being performed. For treatment, the connection could be opened and attached to the extracorporeal circuit. This arrangement preserved access between sessions and made long-term, repeated hemodialysis possible. Clyde Shields was the first patient treated using this approach. (pmc.ncbi.nlm.nih.gov)\n\nAn internal, surgically created arteriovenous fistula subsequently provided an alternative to the external shunt. Michael Brescia, James Cimino, Kenneth Appel, and Baruch Hurwich published their clinical report in November 1966. Connecting an artery directly to a vein increased venous blood flow and allowed repeated needle access without leaving an external arterial–venous bridge in place. Meanwhile, dialysis delivery moved beyond hospital wards: the Seattle Artificial Kidney Center opened in 1962 with three beds accommodating overnight treatment, and Scribner’s team developed home hemodialysis in 1964. These developments combined durable access with patient and family training, making maintenance treatment possible outside the hospital. (nejm.org)\n\nLong-term peritoneal dialysis likewise depended on reliable access and a workable treatment schedule. Henry Tenckhoff’s silicone-rubber indwelling catheter, introduced in 1968, reduced dependence on repeated abdominal puncture. During the 1970s, Jack Moncrief and Robert Popovich developed continuous ambulatory peritoneal dialysis: prolonged dwell periods permitted solute equilibration while patients remained disconnected from machinery between exchanges. Their group’s April 1978 report evaluated nine patients over 136 patient-weeks. At Toronto Western Hospital, Dimitrios Oreopoulos and colleagues adapted the technique to collapsible plastic solution bags, which were easier to handle than glass containers and reduced repeated opening of the fluid pathway. The combination of permanent catheter access, long dwells, and portable exchange equipment established a practical form of ambulatory home treatment. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Epidemiology, Access, and Health-System Organization",
      "text": "Dialysis registries distinguish incidence—new patients beginning treatment during a defined period—from prevalence—patients receiving treatment at a specified time. Counts describe service workload, whereas rates per million population permit comparisons between populations of different sizes; adjustment for age, sex, and other demographic characteristics can substantially change apparent trends. Registries of treated kidney failure do not directly enumerate people who need treatment but cannot obtain it. Dialysis-only totals must also be distinguished from kidney-replacement-therapy totals that include functioning kidney transplants. The United States Renal Data System (USRDS) 2025 Annual Data Report, reporting observations from 2023, recorded 131,564 new cases of treated end-stage kidney disease. Between 2003 and 2023, the annual count increased by 28%, but the demographically adjusted incidence fell from 456 to 362 cases per million population. These are measures of treated kidney failure, not exclusively dialysis initiation. (usrds-adr.niddk.nih.gov)\n\nModality distribution requires a clearly specified denominator and observation point: treatment at initiation differs from treatment among surviving patients because patients subsequently change modalities or undergo transplantation. In the USRDS 2025 report, home dialysis accounted for 15.0% of adults beginning dialysis in 2023 and 14.6% of prevalent adults receiving dialysis that year. Among adults receiving home treatment on December 31, 2023, 67,155 used peritoneal dialysis and 13,670 used home hemodialysis. Thus, a single “home-dialysis” percentage combines two services with different equipment and staffing requirements. The same report documented substantial demographic variation: home treatment was used by 19.1% of Asian and 18.9% of White prevalent dialysis patients, compared with 12.1% of Hispanic and 10.9% of Black patients. Use was higher in less socially deprived neighborhoods and in rural areas. These descriptive associations do not establish the causes of differences or show whether individual modality preferences were met. (usrds-adr.niddk.nih.gov)\n\nInternational comparisons distinguish the existence of a service from its affordability and practical accessibility. An analysis published in 2024 using the International Society of Nephrology’s Global Kidney Health Atlas included 65 low- and lower-middle-income countries. Publicly funded treatment free at the point of delivery was reported in 28% of participating countries for hemodialysis and 15% for peritoneal dialysis; only 41% reported chronic-dialysis accessibility above the study’s 50% threshold. Such country-level survey findings describe health-system capacity, rather than measuring each patient’s treatment experience. They show why the presence of a dialysis unit alone is insufficient evidence of broad access or universal health coverage. (pubmed.ncbi.nlm.nih.gov)\n\nWorkforce, facility distribution, and financing differ markedly between regions. The Africa regional analysis of the 2023 Atlas, published in 2024, included 41 countries and reported a median of 1.12 nephrologists per million population, compared with a global median of 11.8. All participating countries reported shortages in at least some categories of personnel involved in kidney-failure care. Public funding without charges at the point of service was reported by 14 countries for chronic hemodialysis and six for continuous ambulatory peritoneal dialysis. In the North America and Caribbean regional analysis, hemodialysis was available in all 12 responding countries, but the density of hemodialysis centers ranged from 7.8 per million population in Jamaica to 41.5 in Bermuda; peritoneal dialysis was unavailable in Antigua and Barbuda and Saint Lucia. These findings illustrate distinct constraints involving specialist staffing, physical infrastructure, and modality-specific reimbursement. (pmc.ncbi.nlm.nih.gov)\n\nService continuity also depends on water, electricity, transport, and repeated deliveries of consumables, including dialyzers, blood tubing, concentrates, and packaged dialysis solutions. Emergency planning therefore encompasses more than backup machines: it includes generator capacity and fuel, alternative water supplies compatible with treatment requirements, accessible clinical records, supplier arrangements, and agreements with other facilities to receive displaced patients. The Centers for Medicare & Medicaid Services’ facility-planning manual addresses utility failures, supply inventories, mutual aid, and patient transportation; the CDC’s 2019 emergency water-supply planning guide addresses assessment of water-dependent services and alternative supplies. A power source alone cannot restore hemodialysis when water treatment, staffing, or consumable supplies remain interrupted. (cms.gov)"
    },
    {
      "heading": "Laboratory Dialysis and Investigational Technologies",
      "text": "In biochemistry, laboratory dialysis removes salts and small reaction components from solutions containing proteins or other macromolecules. A sample is enclosed in membrane tubing, a cassette, or a small-volume device and immersed in an external buffer. Small solutes undergo diffusion across the membrane, while sufficiently large molecules remain inside. Desalting reduces the concentration of diffusible salts; buffer exchange replaces one buffering system with another as the original components diffuse outward and replacement components diffuse inward. Applications include removing excess labeling reagents and reaction byproducts after protein biotinylation or cross-linking. The method does not efficiently remove contaminants that aggregate or associate with retained macromolecules, even when their individual molecular masses are small. (documents.thermofisher.com)\n\nA membrane’s molecular-weight cutoff (MWCO) is an operational retention rating, not a sharp boundary between molecules that pass and molecules that remain. Thermo Fisher’s laboratory specifications, for example, define it using approximately 90% retention after 17 hours of dialysis. Molecular shape matters: an extended molecule may cross a membrane that retains a globular protein of similar mass. Passage becomes slow near the cutoff, so dialysis is poorly suited to separating similarly sized proteins. External-buffer volume determines the attainable reduction in freely diffusible contaminants. Assuming fixed volumes, complete equilibration, and initially contaminant-free buffer, the fraction remaining after one exchange is \\(V_s/(V_s+V_b)\\), where \\(V_s\\) and \\(V_b\\) are sample and buffer volumes. A 1 mL sample against 200 mL buffer therefore retains approximately \\(1/201\\) of its initial contaminant concentration; fresh buffer restores the gradient for further removal. (documents.thermofisher.com)\n\nMembrane compatibility also affects recovery. Regenerated cellulose generally has greater solvent resistance and thermal stability than cellulose ester membranes, but compatibility depends on the material and solution conditions. Nonspecific binding to the membrane can reduce protein recovery, particularly in dilute samples. Differences in solute concentration can cause osmotic water movement and change sample volume. Membrane area relative to sample volume, temperature, agitation, and the frequency of buffer replacement influence exchange rates independently of the nominal MWCO. (thermofisher.com)\n\nSorbent-based dialysate regeneration addresses a different engineering problem: reducing the fluid supply needed for medical dialysis by cleaning and recirculating spent dialysate. In the wearable artificial kidney investigated by Victor Gura and colleagues, urease converted urea into ammonia and carbonate; zirconium phosphate captured ammonia and other cations, while additional sorbents removed other solutes. Electrolytes required replenishment, and carbon dioxide production required gas removal. Their 2016 report described a nonrandomized, hospital-monitored feasibility study involving seven patients, five of whom completed 24 hours. Mean urea clearance was \\(17 \\pm 10\\) mL/min, and no serious adverse events occurred during observation. However, the trial stopped after the seventh participant because of technical problems, including excessive carbon dioxide bubbles and variable blood and dialysate flows. These findings established short-term feasibility, not long-term safety, unsupervised usability, or improved survival. (pmc.ncbi.nlm.nih.gov)\n\nImplantable bioartificial kidney research separates filtration from proposed cellular functions. One experimental design combines a silicon nanopore hemofilter, intended to use the body’s vascular pressure for filtration, with a bioreactor containing renal tubular epithelial cells. The cellular component is intended to reabsorb water and selected solutes and provide metabolic functions that a filter alone cannot reproduce. A 2023 proof-of-concept study implanted bioreactors containing human renal cells into five healthy pigs for three or seven days. Cell viability remained above 90%, with preserved transporter expression and vitamin D activation. The animals received antiplatelet treatment but no immunosuppression or therapeutic systemic anticoagulation. This experiment tested a bioreactor component, not a complete kidney replacement: it did not demonstrate sustained treatment of kidney failure or clinical effectiveness in humans. (pmc.ncbi.nlm.nih.gov)"
    }
  ],
  "links": [
    "diffusion",
    "medicine",
    "kidney",
    "electrolyte",
    "homeostasis",
    "protein",
    "health-system",
    "biochemistry",
    "organ-transplantation",
    "chronic-kidney-disease",
    "permeability",
    "osmosis",
    "edema",
    "metabolism",
    "erythrocyte",
    "anemia",
    "quality-of-life",
    "nutrition",
    "randomized-controlled-trial",
    "polymer",
    "cellulose",
    "pressure",
    "surgery",
    "thrombosis",
    "anatomy",
    "water",
    "electricity",
    "blood-test",
    "bacteria",
    "hemolysis",
    "inflammation",
    "hemoglobin",
    "mortality-rate",
    "cardiovascular-disease",
    "fatigue",
    "confounding",
    "palliative-care",
    "informed-consent",
    "incidence",
    "prevalence",
    "universal-health-coverage",
    "infrastructure"
  ],
  "sources": [
    {
      "title": "Thermo Scientific High-performance Dialysis Products",
      "url": "https://assets.thermofisher.com/TFS-Assets/LSG/brochures/1602457-High-Performance-Dialysis-Guide.pdf"
    },
    {
      "title": "Hemodialysis - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis"
    },
    {
      "title": "Peritoneal Dialysis - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/peritoneal-dialysis"
    },
    {
      "title": "Choosing a Treatment for Kidney Failure - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/choosing-treatment"
    },
    {
      "title": "KDIGO Announces Publication of the Nomenclature for Kidney Function and Disease Conference Report and Glossary",
      "url": "https://kdigo.org/kdigo-announces-publication-of-the-nomenclature-for-kidney-function-and-disease-conference-report-and-glossary/"
    },
    {
      "title": "Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference",
      "url": "https://kdigo.org/wp-content/uploads/2018/10/Nomenclature-Conference-Report.pdf"
    },
    {
      "title": "KDIGO Clinical Practice Guideline for Acute Kidney Injury",
      "url": "https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf"
    },
    {
      "title": "Chapter 5: Acute Kidney Injury",
      "url": "https://www.niddk.nih.gov/-/media/Files/USRDS/2017--Previous-ADR/CKD/v1_c05_aki_17.pdf"
    },
    {
      "title": "Device Performance of a Tubular Membrane Dialyzer Incorporating Ultrafiltration Effects on the Dialysis Efficiency",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10303233/"
    },
    {
      "title": "Section II – Hemodialysis Review",
      "url": "https://freseniusmedicalcare.com/content/dam/fmcna/live/technical-training/documents/training-manual/490114_Rev_E.pdf"
    },
    {
      "title": "An experimental and numerical study of the flow and mass transfer in a model of the wearable artificial kidney dialyzer",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2881054/"
    },
    {
      "title": "Strategy to Expand High-Volume Hemodiafiltration Worldwide",
      "url": "https://freseniusmedicalcare.com/en/media/multimedia/publications/amr/2024-amr-hemodiafiltration/"
    },
    {
      "title": "Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis",
      "url": "https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0147159&type=printable"
    },
    {
      "title": "Numerous protein-bound solutes are cleared by the kidney with high efficiency",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3758437/"
    },
    {
      "title": "Contribution of Residual Function to Removal of Protein-Bound Solutes in Hemodialysis",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3052218/"
    },
    {
      "title": "Anemia in Chronic Kidney Disease - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/anemia"
    },
    {
      "title": "Mineral & Bone Disorder in Chronic Kidney Disease - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/mineral-bone-disorder"
    },
    {
      "title": "Making Sense of CKD",
      "url": "https://www2.niddk.nih.gov/-/media/Files/Health-Information/Health-Professionals/Kidney-Disease/ckd-primary-care-guide-508.pdf"
    },
    {
      "title": "Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference",
      "url": "https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-in-press.pdf"
    },
    {
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease",
      "url": "https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf"
    },
    {
      "title": "A randomized, controlled trial of early versus late initiation of dialysis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20581422/"
    },
    {
      "title": "Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4422246/"
    },
    {
      "title": "LITHIUM",
      "url": "https://www.extrip-workgroup.org/lithium"
    },
    {
      "title": "METHANOL",
      "url": "https://www.extrip-workgroup.org/methanol"
    },
    {
      "title": "2008T Hemodialysis Machine Operator's Manual",
      "url": "https://freseniusmedicalcare.com/content/dam/fmcna/live/support/documents/operator%27s-manuals---hemodialysis-%28hd%29/2008t-operator%27s-manuals/490122_Rev_AE.pdf"
    },
    {
      "title": "Performance and Hemocompatibility of a Novel Polysulfone Dialyzer: A Randomized Controlled Trial",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8791382/"
    },
    {
      "title": "Choosing a Dialyzer",
      "url": "https://freseniusmedicalcare.com/en-us/insights/articles/choosing-a-dialyzer/"
    },
    {
      "title": "FX dialyzers",
      "url": "https://freseniusmedicalcare.com/en/healthcare-professionals/hemodialysis/dialyzers/fx-dialyzers/"
    },
    {
      "title": "Optiflux High Flux E-Beam Instructions for Use",
      "url": "https://freseniusmedicalcare.com/content/dam/fmcna/live/support/documents/instructions-for-use/hemodialyzers---ifus/DOP_0000268322_Optiflux_%20High_Flux_E-Beam_Artwork.pdf"
    },
    {
      "title": "Renal Association Clinical Practice Guideline on Haemodialysis",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6798406/"
    },
    {
      "title": "Renal Association Clinical Practice Guideline: Haemodialysis",
      "url": "https://www.ukkidney.org/sites/default/files/FINAL-HD-Guideline.pdf"
    },
    {
      "title": "NIDDK Central Repository - Hemodialysis Fistula Maturation Consortium (HFMC)",
      "url": "https://repository.niddk.nih.gov/study/84"
    },
    {
      "title": "KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update",
      "url": "https://www.kidney.org/sites/default/files/2026-07/2019-kdoqi-guideline-vascular-access.pdf"
    },
    {
      "title": "Detection and Management of Clinically Significant AV Access Lesion (Stenosis/Thrombosis)",
      "url": "https://www.kidney.org/sites/default/files/vait-15_detection_management_clinically_significant_av_access_lesion-stenosis_thrombosis.pdf"
    },
    {
      "title": "Management of Steal or AV Access-related Hand Ischemia",
      "url": "https://www.kidney.org/sites/default/files/vait-18_management_of_steal_or_av_access-related_hand_ischemia.pdf"
    },
    {
      "title": "Infections and Patients on Dialysis",
      "url": "https://www.cdc.gov/dialysis-safety/about/index.html"
    },
    {
      "title": "MMWR, Volume 72, Issue 6 — February 10, 2023",
      "url": "https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7206-h.pdf"
    },
    {
      "title": "The National Kidney Foundation Releases Comprehensive Guideline for Vascular Access in Dialysis Patients",
      "url": "https://www.kidney.org/press-room/national-kidney-foundation-releases-comprehensive-guideline-vascular-access-dialysis"
    },
    {
      "title": "DailyMed - DIANEAL peritoneal dialysis solutions",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa268d3f-7389-4f25-801f-5d4825495f08"
    },
    {
      "title": "ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33563110/"
    },
    {
      "title": "DailyMed - EXTRANEAL peritoneal dialysis solution",
      "url": "https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b85158-b0d6-4855-9d07-8d1b3ad9ab71"
    },
    {
      "title": "Prismaflex Operator’s Manual",
      "url": "https://renalcareus.baxter.com/sites/g/files/ebysai2641/files/2020-09/Prismaflex_7_xx_Operators_Manual.pdf"
    },
    {
      "title": "Prismaflex Operator’s Manual",
      "url": "https://usrenalacute.baxter.com/sites/g/files/ebysai3231/files/2020-09/Prismaflex_7_xx_Operators_Manual.pdf"
    },
    {
      "title": "KDIGO Clinical Practice Guideline for Acute Kidney Injury",
      "url": "https://kdigo.org/wp-content/uploads/2019/01/KDIGO-2012-AKI-Guideline-English.pdf"
    },
    {
      "title": "Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference",
      "url": "https://kdigo.org/wp-content/uploads/2018/02/KDIGO-AKI-Controversies-Conf-FINAL.pdf"
    },
    {
      "title": "Kidney Failure Treatment Options - Comparison Chart - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/choosing-treatment/comparison-chart"
    },
    {
      "title": "Teaching peritoneal dialysis: A position paper for the International Society for Peritoneal Dialysis",
      "url": "https://ispd.org/wp-content/uploads/chow-et-al-2025-teaching-peritoneal-dialysis-a-position-paper-for-the-international-society-for-peritoneal-dialysis.pdf"
    },
    {
      "title": "Home Hemodialysis | National Kidney Foundation",
      "url": "https://www.kidney.org/kidney-topics/home-hemodialysis?page=1"
    },
    {
      "title": "For Home Hemodialysis",
      "url": "https://www.kidney.org/sites/default/files/2024-10/11-10-0807_2206_PatBro_PlanForEmergP.pdf"
    },
    {
      "title": "How-to-Guide: Implementing Incremental Haemodialysis",
      "url": "https://skc.ukkidney.org/static/how-to/10.%20How-to-Guide%20Implementing%20Incremental%20Haemodialysis.pdf"
    },
    {
      "title": "NKF KDOQI Guidelines: Methods of Measuring and Expressing the Hemodialysis Dose",
      "url": "https://kidneyfoundation.cachefly.net/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide2.htm"
    },
    {
      "title": "NKF KDOQI Guidelines: Methods for Postdialysis Blood Sampling",
      "url": "https://kidneyfoundation.cachefly.net/professionals/KDOQI/guideline_upHD_PD_VA/hd_guide3.htm"
    },
    {
      "title": "NKF KDOQI Guidelines: Clinical Practice Recommendations for Measuring and Expressing the Hemodialysis Dose",
      "url": "https://kidneyfoundation.cachefly.net/professionals/KDOQI/guideline_upHD_PD_VA/hd_rec2.htm"
    },
    {
      "title": "NKF KDOQI Guidelines: Peritoneal Dialysis Solute Clearance Targets and Measurements",
      "url": "https://kidneyfoundation.cachefly.net/professionals/KDOQI/guideline_upHD_PD_VA/pd_guide2.htm"
    },
    {
      "title": "KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Peritoneal Dialysis Adequacy",
      "url": "https://www.kidney.org/sites/default/files/docs/12-50-0210_jag_dcp_guidelines-pd_oct06_sectionb_ofc.pdf"
    },
    {
      "title": "NATURALYTE® Liquid Acid Concentrate For Bicarbonate Hemodialysis",
      "url": "https://freseniusmedicalcare.com/content/dam/fmcna/live/support/documents/instructions-for-use/naturalyte-bottles---ifus/08-1231-3.pdf"
    },
    {
      "title": "Liquid Sodium Bicarbonate Concentrate",
      "url": "https://freseniusmedicalcare.com/en-us/products/disposables/concentrates/liquid-sodium-bicarbonate-concentrate/"
    },
    {
      "title": "D. Water",
      "url": "https://www.cdc.gov/infection-control/hcp/environmental-control/water.html"
    },
    {
      "title": "Part II. Recommendations for Environmental Infection Control in Health-Care Facilities",
      "url": "https://www.cdc.gov/infection-control/hcp/environmental-control/recommendations.html"
    },
    {
      "title": "AQUAboss nX — a demand-driven Water Treatment System for Dialysis",
      "url": "https://www.bbraun.com/en/products-and-solutions/therapies/extracorporeal-blood-treatment-therapies/hemodialysis/aquaboss-nx.html"
    },
    {
      "title": "Best Practices for Bloodstream Infection Prevention in Dialysis Setting",
      "url": "https://www.cdc.gov/dialysis-safety/hcp/clinical-safety/"
    },
    {
      "title": "Environmental Surface Disinfection in Dialysis Facilities: Notes for Clinical Managers",
      "url": "https://www.cdc.gov/dialysis-safety/media/pdfs/env-notes-508.pdf"
    },
    {
      "title": "Recommendations for Preventing Transmission of Infections Among Chronic Hemodialysis Patients",
      "url": "https://www.cdc.gov/Mmwr/Preview/Mmwrhtml/rr5005a1.htm"
    },
    {
      "title": "Dialysis Wall Boxes and Drains",
      "url": "https://cdc.gov/dialysis-safety/hcp/recommendations-resources/dialysis-wall-boxes-and-drains.html"
    },
    {
      "title": "Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7215236/"
    },
    {
      "title": "Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5293333/"
    },
    {
      "title": "ISPD Catheter-related Infection Recommendations: 2023 Update",
      "url": "https://ispd.org/wp-content/uploads/ISPD-Catheter-related-Infection-Recommendations-2023-Update.pdf"
    },
    {
      "title": "Complications of Peritoneal Dialysis Part I: Mechanical Complications",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11168815/"
    },
    {
      "title": "NKF KDOQI Guidelines: Dietary Protein Intake in Maintenance Hemodialysis",
      "url": "https://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_nutrition/nut_a15.html"
    },
    {
      "title": "Healthy Eating for Adults with Chronic Kidney Disease",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/healthy-eating-adults-chronic-kidney-disease?dkrd=nkdep.nih.gov%2Fresources%2Feating-right.shtml"
    },
    {
      "title": "Eating & Nutrition for Peritoneal Dialysis",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/peritoneal-dialysis/eating-nutrition"
    },
    {
      "title": "Eating & Nutrition for Hemodialysis",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis/eating-nutrition"
    },
    {
      "title": "Simple Formula for Predicting Drug Removal Rates During Hemodialysis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29987905/"
    },
    {
      "title": "Gabapentin Tablets: Prescribing Information",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=35004f84-90ae-45f0-a2ba-653dec507229"
    },
    {
      "title": "Anemia in CKD – KDIGO",
      "url": "https://kdigo.org/guidelines/anemia-%20in-ckd/"
    },
    {
      "title": "KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6340919/"
    },
    {
      "title": "Annual Data Report: Mortality, 2025",
      "url": "https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/6-mortality"
    },
    {
      "title": "Managing the symptom burden associated with maintenance dialysis: conclusions from a KDIGO Controversies Conference",
      "url": "https://kdigo.org/wp-content/uploads/2023/08/KDIGO-Symptoms-Based-Complications-in-Dialysis-Conference-Report_Final.pdf"
    },
    {
      "title": "NIDDK 2023 Post-Dialysis Fatigue Executive Summary",
      "url": "https://www.niddk.nih.gov/-/media/Files/News/Meetings/NIDDK-2023-Post-Dialysis-Fatigue-Executive-Summary_508.pdf"
    },
    {
      "title": "Kidney Disease in Children — NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/children"
    },
    {
      "title": "Helping Your Child Adapt to Life with Chronic Kidney Disease — NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/children/helping-child-adapt-life-chronic-kidney-disease"
    },
    {
      "title": "Home dialysis: conclusions from a KDIGO Controversies Conference",
      "url": "https://kdigo.org/wp-content/uploads/2023/04/Home-Dialysis-Conclusions-from-a-KDIGO-Controversies-Conference.pdf"
    },
    {
      "title": "Kidney Transplant - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/kidney-transplant"
    },
    {
      "title": "Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference",
      "url": "https://kdigo.org/wp-content/uploads/2023/11/KDIGO-Management-of-the-Kidney-Allograft-Controversies-Conference-Report_Dec_2023_Final.pdf"
    },
    {
      "title": "KDIGO Clinical Practice Guideline for Acute Kidney Injury",
      "url": "https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf?trk=public_post_comment-text"
    },
    {
      "title": "Conservative Management for Kidney Failure - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/conservative-management"
    },
    {
      "title": "Stopping or Not Starting Dialysis",
      "url": "https://www.kidney.org/kidney-topics/stopping-or-not-starting-dialysis"
    },
    {
      "title": "Shared Decision Making in Dialysis: Clinical Practice Guideline (Renal Physicians Association)",
      "url": "https://www.kidneysupportivecare.org/shared-decision-making-dialysis-clinical-practice-guideline-renal-physicians-association"
    },
    {
      "title": "Journal of Nephrology Social Work: Dialysis Withdrawal and Shared Decision-Making",
      "url": "https://www.kidney.org/sites/default/files/v26_a5.pdf"
    },
    {
      "title": "Advance Directives",
      "url": "https://www.kidney.org/kidney-topics/advance-directives?page=1"
    },
    {
      "title": "A Brief History of Hemodialysis",
      "url": "https://urologichistory.museum/Documents/Annual-Meeting/Exhibits/Renal-Retrospective-2017.pdf"
    },
    {
      "title": "Remarkable kidneys",
      "url": "https://blog.sciencemuseum.org.uk/remarkable-kidneys/"
    },
    {
      "title": "Prof.dr. Willem Johan Kolff (1911-2009)",
      "url": "https://www.kolff.nl/eng/his_1060/"
    },
    {
      "title": "Vascular access for hemodialysis: A perpetual challenge",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6848759/"
    },
    {
      "title": "Northwest Kidney Centers celebrates 55th anniversary, launches oral history video collection",
      "url": "https://www.nwkidney.org/news/northwest-kidney-centers-celebrates-55th-anniversary-launches-oral-history-video-collection/"
    },
    {
      "title": "Making dialysis safer",
      "url": "https://www.research.va.gov/research_in_action/Making-dialysis-safer.cfm"
    },
    {
      "title": "Our History",
      "url": "https://www.nwkidney.org/about-us/our-history/"
    },
    {
      "title": "The role of technological progress vs. accidental discoveries and clinical experience in the evolution of dialysis",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3843571/"
    },
    {
      "title": "The Birth and Development of Continuous Ambulatory Peritoneal Dialysis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27951554/"
    },
    {
      "title": "Annual Data Report | USRDS: Incidence and Prevalence",
      "url": "https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/1-incidence-and-prevalence"
    },
    {
      "title": "Annual Data Report | USRDS: Home Dialysis",
      "url": "https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/3-home-dialysis"
    },
    {
      "title": "Landscape of kidney replacement therapy provision in low- and lower-middle income countries: A multinational study from the ISN-GKHA",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39621612/"
    },
    {
      "title": "Capacity for the management of kidney failure in the International Society of Nephrology Africa region: report from the 2023 ISN Global Kidney Atlas (ISN-GKHA)",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11010621/"
    },
    {
      "title": "Capacity for the management of kidney failure in the International Society of Nephrology North America and the Caribbean region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11010606/"
    },
    {
      "title": "Emergency Preparedness for Dialysis Facilities",
      "url": "https://www.cms.gov/esrdnetworkorganizations/downloads/emergencypreparednessforfacilities2.pdf"
    },
    {
      "title": "Emergency Water Supply Planning Guide for Hospitals and Healthcare Facilities",
      "url": "https://www.cdc.gov/water-emergency/media/pdfs/2024/07/emergency-water-supply-planning-guide-2019-508.pdf"
    },
    {
      "title": "Optimized Products for Easier, Efficient Dialysis",
      "url": "https://documents.thermofisher.com/TFS-Assets/LSG/brochures/1602457-High-Performance-Dialysis-Guide.pdf"
    },
    {
      "title": "Dialysis: an overview",
      "url": "https://www.thermofisher.com/TFS-Assets/LSG/brochures/TR0020-Dialysis-overview.pdf"
    },
    {
      "title": "Dialysis Methods for Protein Research",
      "url": "https://www.thermofisher.com/de/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/dialysis-methods-protein-research.html"
    },
    {
      "title": "A wearable artificial kidney for patients with end-stage renal disease",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4936831/"
    },
    {
      "title": "Feasibility of an implantable bioreactor for renal cell therapy using silicon nanopore membranes",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10465514/"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}